Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 1-(4-(1-((e)-4-cyclohexyl-3-trifluoromethylbenzyloxyimino)-ethyl)-2-ethylbenzyl)-azetidine-3-carboxylic Acid
2. Baf-312
3. Baf312
4. Mayzent
5. Siponimod
1. Siponimod Hemifumarate
2. Nvp-baf312-aea
3. 1234627-85-0
4. Siponimod Fumaric Acid
5. Siponimod Hemifumaric Acid
6. Z7g02xz0m6
7. Siponimod Fumarate (usan)
8. Siponimod Fumarate [usan]
9. Siponimod Fumaric Acid (jan)
10. Siponimod Fumaric Acid [jan]
11. Baf-312
12. 3-azetidinecarboxylic Acid, 1-((4-((1e)-1-(((4-cyclohexyl-3-(trifluoromethyl)phenyl)methoxy)imino)ethyl)-2-ethylphenyl)methyl)-, (2e)-2-butenedioate (2:1)
13. Mayzent (tn)
14. Unii-z7g02xz0m6
15. Chembl4298150
16. Ex-a4633
17. Siponimod Fumarate [who-dd]
18. Siponimod Fumarate [orange Book]
19. Siponimod Fumaric Acid [orange Book]
20. D11072
21. (e)-1-(4-(1-(((4-cyclohexyl-3-(trifluoromethyl)benzyl)oxy)imino)ethyl)-2-ethylbenzyl)azetidine-3-carboxylic Acid Compound With Fumaric Acid (2:1)
22. (e)-1-(4-(1-(((4-cyclohexyl-3-(trifluoromethyl)benzyl)oxy)imino)ethyl)-2-ethylbenzyl)azetidine-3-carboxylicacidcompoundwithfumaricacid(2:1)
23. Bis-(1-((4-((1e)-1-(((4-cyclohexyl-3-(trifluoromethyl)phenyl)methoxy)imino)ethyl)-2-ethylphenyl)methyl)azetidine-3-carboxylic Acid) (2e)-but-2-enedioate
Molecular Weight | 1149.3 g/mol |
---|---|
Molecular Formula | C62H74F6N4O10 |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 20 |
Rotatable Bond Count | 20 |
Exact Mass | 1148.53091354 g/mol |
Monoisotopic Mass | 1148.53091354 g/mol |
Topological Polar Surface Area | 199 Ų |
Heavy Atom Count | 82 |
Formal Charge | 0 |
Complexity | 896 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 3 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 3 |
Mayzent is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity.
Sphingosine 1 Phosphate Receptor Modulators
Agents that affect the function of G-protein coupled SPHINGOSINE 1-PHOSPHATE RECEPTORS. Their binding to the receptors blocks lymphocyte migration and are often used as IMMUNOSUPPRESSANTS. (See all compounds classified as Sphingosine 1 Phosphate Receptor Modulators.)
L04
Market Place
ABOUT THIS PAGE
A Siponimod fumarate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Siponimod fumarate, including repackagers and relabelers. The FDA regulates Siponimod fumarate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Siponimod fumarate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Siponimod fumarate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Siponimod fumarate supplier is an individual or a company that provides Siponimod fumarate active pharmaceutical ingredient (API) or Siponimod fumarate finished formulations upon request. The Siponimod fumarate suppliers may include Siponimod fumarate API manufacturers, exporters, distributors and traders.
click here to find a list of Siponimod fumarate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Siponimod fumarate DMF (Drug Master File) is a document detailing the whole manufacturing process of Siponimod fumarate active pharmaceutical ingredient (API) in detail. Different forms of Siponimod fumarate DMFs exist exist since differing nations have different regulations, such as Siponimod fumarate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Siponimod fumarate DMF submitted to regulatory agencies in the US is known as a USDMF. Siponimod fumarate USDMF includes data on Siponimod fumarate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Siponimod fumarate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Siponimod fumarate suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Siponimod fumarate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Siponimod fumarate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Siponimod fumarate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Siponimod fumarate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Siponimod fumarate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Siponimod fumarate suppliers with NDC on PharmaCompass.
Siponimod fumarate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Siponimod fumarate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Siponimod fumarate GMP manufacturer or Siponimod fumarate GMP API supplier for your needs.
A Siponimod fumarate CoA (Certificate of Analysis) is a formal document that attests to Siponimod fumarate's compliance with Siponimod fumarate specifications and serves as a tool for batch-level quality control.
Siponimod fumarate CoA mostly includes findings from lab analyses of a specific batch. For each Siponimod fumarate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Siponimod fumarate may be tested according to a variety of international standards, such as European Pharmacopoeia (Siponimod fumarate EP), Siponimod fumarate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Siponimod fumarate USP).
LOOKING FOR A SUPPLIER?